Coeptis Therapeutics Inc. (COEP)
Company Description
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer.
Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.
The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease.
Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
| Country | United States |
| IPO Date | Dec 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | David Mehalick |
Contact Details
Address: 105 Bradford Road Wexford, Pennsylvania United States | |
| Website | https://coeptispharma.com |
Stock Details
| Ticker Symbol | COEP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001759186 |
| CUSIP Number | 19207C104 |
| ISIN Number | US19207A1088 |
| Employer ID | 98-1465952 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Mehalick | Co-Founder, Chairman of the Board, Chief Executive Officer & President |
| Brian Cogley M.B.A. | Chief Financial Officer |
| Christine Elise Sheehy | Co-Founder and Vice President of Compliance & Corporate Secretary |
| Daniel Alexander Yerace | Co-Founder, Vice President of Operations & Director |
| Dr. Colleen Delaney M.D., M.Sc. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 03, 2025 | 10-K/A | [Amend] Annual Report |
| May 15, 2025 | 424B3 | Filing |
| May 15, 2025 | 424B3 | Filing |
| May 15, 2025 | 424B3 | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| Apr 28, 2025 | 424B3 | Filing |
| Apr 28, 2025 | 424B3 | Filing |
| Apr 28, 2025 | 424B3 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 424B4 | Filing |